Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
11/2003
11/20/2003US20030215840 Identifying compounds capable of treating atherosclerosis, reperfusion injury, hypertension, restenosis, arterial inflammation, heart failure, thrombosis and endothelial cell disorders
11/20/2003US20030215835 Designing oligonucleotides for diagnosing, monitoring, prognosticating, preventing or treating metabolic disorders; forensics; gene therapy; drug screening
11/20/2003US20030215831 Renal regulatory elements and methods of use thereof
11/20/2003US20030215823 Uses of galanin GALR2 receptors
11/20/2003US20030215820 Regulators of type-1tumor necrosis factor receptor and other cytokine receptor shedding
11/20/2003US20030215803 Isolated polynucleotide which hybridizes to given sequence; use in diagnosing cancer and for inhibiting tumor growth
11/20/2003US20030215792 Nucleic acid molecule comprising a nucleic acid sequence coding for a chemokine, a neuropeptide precursor, or at least on neuropeptide
11/20/2003US20030215489 Chemosensitizing with liposomes containing oligonucleotides
11/20/2003US20030215466 Which is incapable of reproduction within human cell lines; for treatment of human immunodeficency virus
11/20/2003US20030215463 Replication defective herpes virus vector has a deletion of at least a fragment of a UL29 gene that is replaced with a heterologous sequence encoding an antigen from a specific infectious disease agent
11/20/2003US20030215460 Methods and compositions for inducing an immune response
11/20/2003US20030215458 Comprise wilms' tumor suppressor gene(wt1) polynucleotide, polypeptide, antigen-presenting cell presenting WT1 polypeptide, antibody that specifically binds to or T cell that specifically reacts with WT1 polypeptide; immunotherapy
11/20/2003US20030215452 Methods and compositions for treating hematological disorders using 131, 148, 199, 12303, 13906, 15513, 17822, 302, 5677, 194, 14393, 28059, 7366, 12212, 1981, 261, 12416, 270, 1410, 137, 1871, 13051, 1847, 1849, 15402, 340, 10217, 837, 1761, 8990 or 13249 molecules
11/20/2003US20030215451 In treatment (including prevention) or identification of a human subject at risk of tissue damage, preferably liver or heart tissue damage
11/20/2003US20030215445 Concerns an 88 kDa glycoprotein growth factor ("GP88" or "PCDGF") and compositions and methods which affect the expression and biological activity of GP88; useful for diagnosis and treatment of diseases
11/20/2003US20030215442 Methods and compositions for the treatment or prevention of immune disorders using combination therapy
11/20/2003US20030215432 Increasing blood-brain barrier permeability for drug deliverying by administering a hyaluronidase and active materials
11/20/2003US20030215428 Methods for stimulating nervous system regeneration and repair by regulating arginase I and polyamine synthesis
11/20/2003US20030215427 CE7-specific redirected immune cells
11/20/2003US20030215424 Method of modulating angiogenesis
11/20/2003US20030215423 Drug delivery a genetic engineered vector, encoding protein hormone in vivo; a helper dependent adenoviral vector
11/20/2003US20030215422 Aav4 vector and uses thereof
11/20/2003US20030215420 Novel therapeutic treatment of chronic obstructive pulmonary disease
11/20/2003US20030215402 Porphyromonas gingivalis recombinant proteins and truncations
11/20/2003US20030215395 Cationic amine polymer, cationic peptide or cationic carbohydrate and at least one degradable linker molecule connecting said cationic molecules in a branched arrangement
11/20/2003CA2492044A1 Ldl receptor-related proteins 1 and 2 and treatment of bone or cartilage conditions
11/20/2003CA2485655A1 Recombinant fowlpox virus
11/20/2003CA2485400A1 Methylated immunostimulatory oligonucleotides and methods of using the same
11/20/2003CA2485373A1 Epha2 monoclonal antibodies and methods of use thereof
11/20/2003CA2485256A1 Pathogen vaccines and methods for using the same
11/20/2003CA2484669A1 Brachyspira hyodysenteriae vaccine
11/20/2003CA2484607A1 Methods and compositions for inducing an immune response
11/20/2003CA2484266A1 Cancer vaccines and methods of using the same
11/20/2003CA2484144A1 Eif-5a nucleic acids for inhibiting apoptosis
11/20/2003CA2483142A1 Use of vegf for treating bone defects
11/20/2003CA2462203A1 Methods and products for enhancing immune responses using imidazoquinoline compounds
11/19/2003EP1362916A2 Human tumor necrosis factor delta and epsilon
11/19/2003EP1362915A1 Nomuraeae rileyi -origin ecdysteroid 22-oxidase and molt hormone inactivation system with the use of the same
11/19/2003EP1362867A2 Control of the ratio of LAP to LIP
11/19/2003EP1362600A1 Pharmaceutical compositions containing decoy and method of using the same
11/19/2003EP1362596A2 Inhibitor of stem cell proliferation and uses thereof
11/19/2003EP1362108A2 Novel human protease and polynucleotides encoding the same
11/19/2003EP1362104A2 T cell receptor variants expressed in mesenchymal cells and uses thereof
11/19/2003EP1362100A2 Novel p53-inducible protein
11/19/2003EP1362097A2 Champ-a cardiac helicase-like factor
11/19/2003EP1362096A2 Pigmentary epithelium cell of the eye, the production thereof and the use of the same for treating diseases of the eye or of the central nervous system
11/19/2003EP1362095A2 Post-partum mammalian placenta, its use and placental stem cells therefrom
11/19/2003EP1361898A2 Modulated release particles for aerosol delivery
11/19/2003EP1361896A2 Localized myocardial injection method for treating ischemic myocardium
11/19/2003EP1361888A2 Method of treating neurologcial diseases
11/19/2003EP1361859A1 Modulated release particles for aerosol delivery
11/19/2003EP1361858A2 Modulated release particles for aerosol delivery
11/19/2003EP0733066B1 Pretargeting methods and compounds
11/18/2003US6649751 Reacting biopolymers with alkylamines and ammonium hydroxide, heating and eluting through columns having ion exchange resins, then recovering the polynuleotides; solid phase synthesis
11/18/2003US6649738 Pancreas-derived plasminogen activator inhibitor
11/18/2003US6649595 FK506 binding proteins (FKBPs); rapamysin derivatives; multimerizing chimeric proteins in genetically engineered cells using said derivatives
11/18/2003US6649410 Method for the development of an HIV vaccine
11/18/2003US6649407 Viral fiber protein for use in the treatment of viral diseases
11/18/2003US6649391 Isolated polynucleotide encoding a polypeptide of given sequence; dephosphorylates MAP(mitogen activated protein)-kinase; used for modulating cell proliferation, differentiation and survival
11/18/2003US6649375 Adenoviral vectors for enhanced gene expression
11/18/2003US6649373 Use of trans-activation and CIS-activation to modulate the persistence of expression of a transgene
11/18/2003US6649372 Which expresses heterologous nucleotide sequences; introducing expression vectors, nucleotprotein, and polymerase into a cell; allowing complex to form; culturing; use in vaccines
11/18/2003US6649366 Methods and compositions related to modulators of annexin and cartilage homeostasis
11/18/2003US6649353 Method for influencing the p53 linkage to target genes
11/18/2003US6649345 Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
11/13/2003WO2003093486A1 In situ generation of viral vectors
11/13/2003WO2003093485A2 Optimization of transgene expression in mammalian cells
11/13/2003WO2003093479A1 Improved raav expression systems and methods for enhancing transduction of mammalian neural cells
11/13/2003WO2003093478A1 Immunoconjugates for the treatment of tumours
11/13/2003WO2003093476A1 Vector with modified protease-dependent tropism
11/13/2003WO2003093469A2 Methods for delivering nucleic acid molecules into cells and assessment thereof
11/13/2003WO2003093455A2 Adenovirus vectors for immunotherapy
11/13/2003WO2003093449A2 Methods for delivery of nucleic acids
11/13/2003WO2003093436A2 Treatment for phenylketonuria
11/13/2003WO2003093431A2 Ablated slam-dependent entry
11/13/2003WO2003093422A2 Novel tissue factor targeted antibodies as anticoagulants
11/13/2003WO2003093419A2 Preventing secondary lymphedema with vegf-d dna
11/13/2003WO2003093409A2 Promoters exhibiting endothelial cell specificity and methods of using same
11/13/2003WO2003093295A2 Secretion signal vectors
11/13/2003WO2003092740A1 Non-viral gene delivery system
11/13/2003WO2003092739A1 Non-viral gene delivery system
11/13/2003WO2003092738A1 Drug- or gene-carrier composition having lowered hemagglutinin activity
11/13/2003WO2003092737A1 Fusions of cytokines and tumor targeting proteins
11/13/2003WO2003092733A1 Chemically activated carboxypolysaccharides and uses
11/13/2003WO2003092732A1 Ph-sensitive polymer
11/13/2003WO2003092724A1 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR
11/13/2003WO2003092717A1 Cancer immunotherapy
11/13/2003WO2003092716A2 Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
11/13/2003WO2003092715A2 Proteins involved in the regulation of energy homeostasis
11/13/2003WO2003092657A1 Microparticles bearing cells and active substances
11/13/2003WO2003092618A2 Materials and methods for prevention and treatment of rna viral diseases
11/13/2003WO2003092612A2 VECTORS HAVING BOTH ISOFORMS OF β-HEXOSAMINIDASE
11/13/2003WO2003092602A2 Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants
11/13/2003WO2003092600A2 Site specific listeria integration vectors and methods for using the same
11/13/2003WO2003092598A2 Treatment for pompe disease
11/13/2003WO2003092594A2 Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use
11/13/2003WO2003092582A2 Chimeric ebola virus envelopes and uses therefor
11/13/2003WO2003092579A2 Compositions and methods for treating cancer with an oncolytic viral agent
11/13/2003WO2003061551A3 Ex-vivo gene therapy of diabetes using iap polypeptides
11/13/2003WO2003052067A3 Vector mediated organelle transfection
1 ... 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 ... 870